Literature DB >> 17560788

Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.

Larry D Bratton1, Bruce Auerbach, Chulho Choi, Lisa Dillon, Jeffrey C Hanselman, Scott D Larsen, Gina Lu, Karl Olsen, Jeffrey A Pfefferkorn, Andrew Robertson, Catherine Sekerke, Bharat K Trivedi, Paul C Unangst.   

Abstract

In an effort to identify hepatoselective inhibitors of HMG-CoA reductase, two series of pyrroles were synthesized and evaluated. Efforts were made to modify (3R,5R)-7-[3-(4-fluorophenyl)-1-isopropyl-4-phenyl-5-phenylcarbamoyl-1H-pyrrol-2-yl]-3,5-dihydroxy-heptanoic acid sodium salt 30 in order to reduce its lipophilicity and therefore increase hepatoselectivity. Two strategies that were explored were replacement of the lipophilic 3-phenyl substituent with either a polar function (pyridyl series) or with lower alkyl substituents (lower alkyl series) and attachment of additional polar moieties at the 2-position of the pyrrole ring. One compound was identified to be both highly hepatoselective and active in vivo. We report the discovery, synthesis, and optimization of substituted pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase for reducing low density lipoprotein cholesterol (LDL-c) in the treatment of hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560788     DOI: 10.1016/j.bmc.2007.05.031

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

1.  Synthesis and Pharmacochemistry of New Pleiotropic Pyrrolyl Derivatives.

Authors:  Markella Konstantinidou; Alice Gkermani; Dimitra Hadjipavlou-Litina
Journal:  Molecules       Date:  2015-09-10       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.